RAS Pathway Interceptor
Non Small Cell Lung, Pancreatic, Colorectal Cancer
DiscoveryActive
Key Facts
Indication
Non Small Cell Lung, Pancreatic, Colorectal Cancer
Phase
Discovery
Status
Active
Company
About Apertor Pharmaceuticals
Apertor Pharmaceuticals is a private, preclinical-stage biotech pioneering a novel approach to disrupt protein-protein interactions (PPIs) in oncology. Its core technology platform develops 'Interceptors,' heterobifunctional small molecules that recruit the abundant intracellular protein FKBP12 to sterically obstruct oncogenic signaling complexes, offering a differentiated mechanism from protein degraders like PROTACs. The company is advancing a pipeline led by a program targeting mTORC1/4E-BP1 in solid tumors and is backed by a team of experienced founders and scientific advisors with deep expertise in chemical biology and drug discovery.
View full company profile